trending Market Intelligence /marketintelligence/en/news-insights/trending/jvkqmzc2jt0agfi_8axo-w2 content esgSubNav
In This List

UK regulator closes pricing investigation on Concordia's eye treatment

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


UK regulator closes pricing investigation on Concordia's eye treatment

The U.K. Competition and Markets Authority is closing an investigation into Concordia International Corp.'s treatment for an eye disease.

The conjunctivitis treatment, Fusidic Acid eye drops, was one of the company's products that the regulator was investigating after a probe related to the pricing of the company's products was opened in October 2016.

Conjunctivitis is an inflammation or swelling of the conjunctiva, a transparent layer of tissue that lines the inner surface of the eyelid and covers the white part of the eye.

The regulator is also looking into the possibility of competition law infringement in which the company overcharged Britain's National Health Service for an essential thyroid medicine, liothyronine tablets.

Other cases with the U.K. authority include a suspected unfair pricing of hydrocortisone tablets and an alleged collusion with Actavis U.K. to prevent cheaper versions of the medicine from entering the market.

The U.K regulator is also investigating the company's international segment for any breaches of U.K. competition law.